Biokin Pharmaceutical

August 27, 2026 11 Min Read

Last updated: August 27, 2026

Company Overview

Sichuan Biokin Pharmaceutical Co., Ltd. (四川百利天恒药业股份有限公司; SSE: 688506), commonly known as Biokin Pharmaceutical or Baili Tianheng, is a Chinese commercial-stage biopharmaceutical company developing innovative oncology medicines, with particular expertise in antibody-drug conjugates (ADCs), bispecific/multispecific antibodies and emerging antibody-radionuclide conjugates (ARCs).

The company’s origins date to 1996, when founder, Chairman, CEO and Chief Science Officer Dr. Zhu Yi established Baili Pharmaceutical. Biokin has subsequently evolved from a conventional Chinese pharmaceutical manufacturer into an integrated innovative biopharmaceutical company spanning drug discovery, clinical development, manufacturing and commercialization. (en.baili-pharm.com, en.baili-pharm.com)

Its headquarters are in Wenjiang District, Chengdu, Sichuan Province, China, while its U.S. subsidiary SystImmune operates an oncology-focused R&D organization in the United States. (ir.baili-pharm.com)

Company	Sichuan Biokin Pharmaceutical Co., Ltd.
Chinese name	四川百利天恒药业股份有限公司
Common names	Biokin Pharmaceutical / Baili Tianheng / 百利天恒
Origins	1996
Founder	Dr. Zhu Yi
Headquarters	Chengdu, Sichuan, China
Business status	Public
Stock exchange	Shanghai Stock Exchange STAR Market
Ticker	688506.SH
A-share listing	January 2023
Hong Kong status	Renewed Main Board listing application filed August 2026; not yet HK-listed as of Aug. 27, 2026
Development stage	Commercial-stage innovative biopharma
Primary therapeutic focus	Oncology
Major modalities	ADCs, bispecific ADCs, GNC multispecific antibodies, ARCs, conventional antibodies and small molecules
Flagship product	Iza-bren (BL-B01D1)
U.S. innovation subsidiary	SystImmune, Inc.
Strategic objective	Build a globally integrated oncology biopharmaceutical company

Biokin describes its long-term strategy as combining the advantages of the North American “0-to-1” innovation ecosystem with China’s “1-to-N” development and scale-up capabilities. The company aims to establish full global commercialization capabilities by 2029. (ir.baili-pharm.com)

Corporate Structure and R&D Model

Biokin has built an unusual cross-Pacific drug-development model.

In the United States, SystImmune focuses primarily on discovery and development of innovative antibodies and ADCs targeting malignant tumors.

In China, Baili Pharmaceutical and Bailidote/Baili-Bio conduct innovative biologic and chemical-drug research, clinical development, manufacturing and commercialization.

The broader group also includes businesses such as Guorui Pharmaceutical and Jingxi Pharmaceutical. (en.baili-pharm.com)

This structure supports Biokin’s strategy of discovering globally competitive molecules while taking advantage of China’s clinical-development, manufacturing and commercialization infrastructure.

Therapeutic Focus

Unlike more diversified Chinese pharmaceutical companies such as Haisco, Biokin’s innovative R&D strategy is now overwhelmingly focused on oncology.

Its pipeline is built around three major next-generation technology areas:

Technology	Description	Representative programs
ADC	Antibody-drug conjugates delivering cytotoxic payloads selectively to tumors	Iza-bren, T-Bren, BL-M14D1, BL-B16D1, BL-M17D1, BL-M09D1
GNC	“Guidance, Navigation & Control” multispecific antibody platform	SI-B001, GNC-077 and other multispecific programs
ARC	Antibody-radionuclide conjugates	BL-ARC002 and emerging ARC programs
Conventional biologics	Monoclonal/bispecific antibodies	Multiple oncology programs
Small molecules	Targeted and other chemical drugs	Selected oncology and established pharmaceutical programs

The company says it has established capabilities covering innovative large-molecule oncology therapeutics, global clinical development and commercial-scale manufacturing, with the objective of ultimately building an integrated global oncology company. (ir.baili-pharm.com)

Flagship Product: Iza-bren (BL-B01D1)

World’s First Approved Bispecific ADC

Izalontamab brengitecan (iza-bren; BL-B01D1) is the centerpiece of Biokin’s transformation.

The molecule is a first-in-class EGFR × HER3 bispecific antibody-drug conjugate. It combines dual targeting of EGFR and HER3 with delivery of a proprietary topoisomerase-I inhibitor payload.

The dual-targeting design allows iza-bren to recognize tumors expressing EGFR and/or HER3 while simultaneously delivering its cytotoxic payload following antibody-mediated internalization. (investors.bms.com)

The molecule entered clinical development in 2021 and Phase III development in 2023. By June 2026, Biokin reported that more than 40 clinical trials, including 19 Phase III studies, were evaluating iza-bren across multiple cancers in China and the United States. (ir.baili-pharm.com, english.sse.com.cn)

Iza-bren Becomes a Commercial Product

2026 marked a critical transition for Biokin: iza-bren moved from being an investigational asset into an approved oncology product.

First Approval — Nasopharyngeal Cancer

On June 22, 2026, Biokin announced the first Chinese regulatory approval of iza-bren for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) whose disease had progressed following prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment. (prnewswire.com)

This was the first regulatory approval worldwide for iza-bren and established the drug as the first commercialized EGFR×HER3 bispecific ADC.

Second Approval — Esophageal Cancer

Less than one month later, on July 17, 2026, iza-bren received its second NMPA approval.

The indication covers adults with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) following progression on platinum-containing chemotherapy and PD-1/PD-L1 therapy. (prnewswire.com)

The rapid sequence of approvals effectively transformed Biokin into a commercial innovative-oncology company.

Iza-bren Phase III Development Program

The commercial opportunity for iza-bren extends far beyond its first two indications.

The drug is being studied across:

Non-small cell lung cancer
Small cell lung cancer
Triple-negative breast cancer
HR+/HER2-negative breast cancer
Nasopharyngeal carcinoma
Esophageal squamous cell carcinoma
Urothelial carcinoma
Ovarian cancer
Other solid tumors

As of mid-2026, Biokin reported 19 Phase III studies within the broader iza-bren development program. Seven indications had received Breakthrough Therapy Designation from China’s CDE, two had entered Priority Review, and one indication had received U.S. FDA Breakthrough Therapy Designation. (english.sse.com.cn)

Five Positive Phase III Readouts

Iza-bren’s clinical story accelerated substantially during 2025–2026.

Phase III study / setting	Development	Result/status
BL-B01D1-303	Pretreated recurrent/metastatic NPC	Primary endpoint met
BL-B01D1-305 / PANKU-Esophagus01	Pretreated recurrent/metastatic ESCC	PFS + OS positive
BL-B01D1-307 / PANKU-Breast02	Pretreated advanced TNBC	PFS + OS positive
BL-B01D1-301	EGFR-mutant NSCLC after TKI	Primary endpoint met
BL-B01D1-306	HR+/HER2− advanced breast cancer after ≥1 chemotherapy	PFS endpoint met – Aug. 2026

The newest result came on August 25, 2026.

At a prespecified interim analysis of BL-B01D1-306, an independent Data Monitoring Committee concluded that iza-bren met the primary endpoint of progression-free survival in patients with unresectable locally advanced, recurrent or metastatic HR-positive/HER2-negative breast cancer who had failed at least one prior chemotherapy regimen. (vcbeathealth.com)

This represented the fifth Phase III trial for iza-bren to meet its primary endpoint and further strengthened the evidence that the molecule may have activity across multiple epithelial tumors.

Triple-Negative Breast Cancer

The Phase III PANKU-Breast02 / BL-B01D1-307 study is another particularly important component of the program.

At the 2026 ASCO Annual Meeting, Biokin/SystImmune and Bristol Myers Squibb reported statistically significant and clinically meaningful improvements in both PFS and OS for iza-bren in heavily pretreated, unresectable locally advanced or metastatic TNBC.

According to the companies, it was the first Phase III trial of a bispecific ADC in TNBC to report positive results for both PFS and OS. (investors.bms.com)

The Chinese NDA for this indication has already been accepted for regulatory review. (english.sse.com.cn)

Selected Innovative Pipeline

Although iza-bren dominates investor attention, Biokin is building a much broader next-generation oncology portfolio.

Candidate	Target / modality	Major indication(s)	Highest disclosed stage*
Iza-bren / BL-B01D1	EGFR × HER3 bispecific ADC	Multiple solid tumors	Approved / Phase III
SI-B001	EGFR × HER3 bispecific antibody	Solid tumors	Phase III
T-Bren / BL-M07D1	HER2 ADC	HER2-expressing tumors	Clinical / registrational development
BL-M14D1	DLL3 ADC	SCLC / neuroendocrine tumors	Phase III
BL-B16D1	Next-generation ADC	Solid tumors	Clinical
BL-M17D1	Next-generation ADC	Solid tumors	Clinical
BL-M09D1	Next-generation ADC	Solid tumors	Phase I
GNC-077	Multispecific GNC antibody	Advanced solid tumors	Phase I
BL-ARC002	Antibody-radionuclide conjugate	Advanced solid tumors	Phase I
Additional GNC programs	Multispecific antibodies	Oncology	Preclinical / clinical
Additional ADC programs	ADC / bispecific ADC	Oncology	Preclinical / clinical
Additional ARC programs	Radio-conjugates	Oncology	Preclinical

*Simplified according to the highest publicly disclosed development stage through August 27, 2026. Individual indications can be at different stages.

Biokin’s pipeline is now broad enough that third-party pipeline databases track numerous ADCs, bispecific/multispecific antibodies and small molecules across its subsidiaries, although the company’s own strategic focus remains concentrated on its highest-value oncology assets. (synapse-patsnap-com.sutd.idm.oclc.org)

BL-M14D1 — DLL3 ADC

One of the most important assets behind iza-bren is BL-M14D1, an ADC targeting DLL3.

The candidate is being developed primarily for small-cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine tumors.

The program has advanced into Phase III development, making BL-M14D1 one of the more mature next-generation candidates in Biokin’s pipeline. (synapse-patsnap-com.sutd.idm.oclc.org)

If successful, BL-M14D1 could give Biokin a second major ADC franchise independent of iza-bren.

T-Bren / BL-M07D1 — HER2 ADC

T-Bren (BL-M07D1) is Biokin’s internally developed HER2-targeting ADC.

The candidate entered clinical development in 2022 and incorporates the company’s proprietary cleavable linker and topoisomerase-I inhibitor payload technology. (ir.baili-pharm.com)

It is being investigated across HER2-expressing solid tumors and represents another attempt to translate Biokin’s ADC platform into a broad oncology franchise.

SI-B001 and the GNC Platform

SI-B001 is an EGFR×HER3 bispecific antibody without an ADC payload.

The molecule entered Phase III development in 2023, making it one of Biokin’s earliest late-stage internally developed innovative biologics. (ir.baili-pharm.com)

Biokin has subsequently expanded its GNC (Guidance, Navigation & Control) multispecific-antibody platform.

One representative program, GNC-077, entered Phase I clinical development in 2024.

The platform is designed to create multispecific molecules capable of more sophisticated tumor targeting and immune regulation than conventional monoclonal or bispecific antibodies.

Expansion Into Antibody-Radionuclide Conjugates

Biokin is now attempting to extend its conjugate expertise beyond ADCs.

BL-ARC002 entered a Phase I clinical study in 2026 for locally advanced or metastatic solid tumors. The study evaluates safety, tolerability, pharmacokinetics and preliminary antitumor activity through dose escalation and expansion. (synapse-patsnap-com.libproxy1.nus.edu.sg)

The program represents the emerging ARC—antibody-radionuclide conjugate—platform highlighted by Biokin as one of its three major next-generation large-molecule oncology technologies alongside ADC and GNC. (ir.baili-pharm.com)

Bristol Myers Squibb Partnership

Biokin’s most important international partnership is its landmark agreement with Bristol Myers Squibb covering iza-bren.

In December 2023, Biokin’s U.S. subsidiary SystImmune and BMS entered a global strategic collaboration and license agreement for the development and commercialization of iza-bren.

The transaction included an $800 million upfront payment and potential total consideration of up to $8.4 billion, making it one of the largest single-asset licensing transactions ever signed by a Chinese biotechnology company and, at announcement, the largest single-asset ADC transaction globally. (baili-pharm.com, english.sse.com.cn)

Iza-bren Rights Structure

Territory	Development / commercialization economics
Mainland China	Biokin retains primary/exclusive commercialization rights; BMS receives agreed royalties
United States	SystImmune/Biokin and BMS jointly develop and commercialize; costs and profits/losses shared
Other ex-China territories	BMS holds exclusive development and commercialization rights
Upfront payment	US$800 million
Potential total deal value	Up to US$8.4 billion
Ex-U.S./China sales	Biokin eligible for tiered royalties

Outside China, iza-bren is therefore being developed jointly through the SystImmune–BMS collaboration, including global pivotal programs in TNBC, NSCLC and urothelial carcinoma. (en.baili-pharm.com, investors.bms.com)

The partnership is strategically important not merely because of its headline value. BMS provides Biokin with a global clinical-development and commercialization infrastructure that would have taken the Chinese company years and substantial capital to build independently.

Commercial Business

Biokin historically generated revenue from an established pharmaceutical portfolio covering areas including:

anesthesia, parenteral nutrition, anti-infectives, pediatrics and traditional Chinese medicines. (ir.baili-pharm.com)

That legacy business remains relevant because it provides Biokin with manufacturing and commercial infrastructure.

However, the company’s economic center of gravity is clearly shifting toward innovative oncology.

The June and July 2026 approvals of iza-bren in NPC and ESCC mark the beginning of this transition. For the first time, Biokin can commercialize the flagship product around which much of its global R&D strategy has been built. (prnewswire.com)

Financial and Funding Position

Biokin’s financial profile is unusual because the BMS transaction created a very large one-time licensing revenue contribution in 2024.

Financial metric	2024	2025	H1 2026
Revenue	RMB5.82B	RMB2.52B	RMB187.3M
Net income/(loss)	RMB3.71B profit	RMB1.05B loss	RMB1.64B loss
Major driver	BMS licensing income	Heavy R&D expansion	Heavy global clinical investment

Biokin reported approximately RMB5.82 billion of revenue in 2024, reflecting in large part licensing income from the BMS collaboration. R&D expense that year reached approximately RMB1.44 billion, nearly doubling annually over the 2022–2024 period. (baili-pharm.com)

In 2025, revenue declined to approximately RMB2.52 billion, while the company recorded a net loss of roughly RMB1.05 billion as development spending accelerated. (marketscreener.com)

The investment intensified further during 2026. For the six months ended June 30, Biokin reported approximately RMB187.3 million in revenue and a RMB1.64 billion net loss, versus RMB1.12 billion of net loss in the comparable 2025 period. (marketscreener.com)

This should not necessarily be interpreted like the losses of an early-stage biotech: Biokin is deliberately funding a very large global oncology program, including numerous Phase III studies, while also building manufacturing and future commercialization capabilities.

Capital Markets and Hong Kong Listing Plans

Biokin became a publicly traded company when it listed on the Shanghai Stock Exchange STAR Market in January 2023, under ticker 688506.SH. (ir.baili-pharm.com)

The company subsequently pursued a dual listing in Hong Kong.

A planned Hong Kong global offering in November 2025 was postponed because of market conditions, meaning Biokin did not become a Hong Kong-listed company at that time. (www1.hkexnews.hk)

The company has now restarted the process.

On August 6, 2026, Biokin filed a renewed application for a Main Board listing with the Hong Kong Stock Exchange.

Accordingly, as of August 27, 2026, Biokin remains:

Publicly listed on the Shanghai STAR Market (688506.SH), with a Hong Kong listing application in progress.

This distinction is important because some financial databases may display the proposed Hong Kong stock code 2615, even though the postponed 2025 offering did not result in a completed listing. (www1.hkexnews.hk)

Latest Clinical and Commercial Developments

Date	Development	Significance
Aug. 25, 2026	BL-B01D1-306 met PFS endpoint in HR+/HER2− breast cancer	5th positive Phase III iza-bren study
Aug. 6, 2026	Renewed Hong Kong listing application filed	Potential additional capital-market access
Jul. 17, 2026	Iza-bren approved for ESCC	Second commercial indication
Jun. 22, 2026	Iza-bren approved for NPC	First-ever commercial approval
Jun. 2026 / ASCO	Positive PFS + OS results in TNBC and ESCC	Strengthened broad-tumor efficacy thesis
2026	BL-ARC002 entered Phase I	Launches clinical ARC platform
2026	Iza-bren global Phase II/III development continues with BMS	Advances international commercialization strategy

Financing Model

Biokin now has four principal sources of capital:

1. Established pharmaceutical sales

The company’s legacy commercial portfolio generates recurring operating revenue.

2. Innovative-drug commercialization

Iza-bren became commercial in China in 2026, opening a potentially much larger long-term revenue stream.

3. Licensing and collaboration payments

The BMS agreement generated an $800 million upfront payment and provides potential milestones and royalties.

4. Public capital markets

Biokin is listed in Shanghai and is seeking an additional Hong Kong listing.

This gives Biokin considerably more financing flexibility than a conventional clinical-stage biotech, although its extremely aggressive global clinical-development strategy also produces substantial cash requirements.

Competitive Position

Biokin has emerged as one of the most closely watched Chinese ADC developers because its strategy differs from many domestic pharmaceutical companies.

Rather than developing a broad collection of unrelated medicines, Biokin is building a concentrated next-generation oncology technology ecosystem.

1. Bispecific ADC Leadership

Iza-bren has validated the company’s bispecific ADC strategy clinically and commercially. Two approvals and five positive Phase III readouts substantially reduce the platform’s earlier proof-of-concept risk.

2. Proprietary ADC Pipeline

Programs such as T-Bren, BL-M14D1, BL-B16D1, BL-M17D1 and BL-M09D1 could potentially demonstrate whether Biokin’s success can be replicated beyond a single molecule.

3. Multispecific GNC Platform

SI-B001, GNC-077 and other GNC candidates provide another route to targeting complex tumor biology without relying exclusively on cytotoxic payloads.

4. ARC Expansion

The move into antibody-radionuclide conjugates potentially extends Biokin’s antibody-targeting capabilities into radiopharmaceutical oncology.

5. Global Development Infrastructure

SystImmune gives the company an internal U.S. R&D presence, while the BMS partnership supplies additional global development and commercialization capabilities.

Outlook

Biokin is undergoing one of the more significant transformations among China’s emerging biopharmaceutical companies.

It began as a conventional pharmaceutical business in 1996, built increasingly sophisticated biologics capabilities, entered the Shanghai STAR Market in 2023 and then attracted international attention through the $8.4 billion potential iza-bren partnership with Bristol Myers Squibb. (ir.baili-pharm.com)

The story entered a new phase in 2026.

Iza-bren is no longer simply a promising Chinese ADC. It is now an approved commercial medicine, with two NMPA-approved indications, multiple additional NDAs/registrational programs, extensive Phase III development and global development underway with BMS. (prnewswire.com)

Most importantly, the expanding Phase III dataset suggests that iza-bren’s potential may not be confined to a narrow biomarker-defined population. Positive studies have now emerged across nasopharyngeal cancer, esophageal cancer, triple-negative breast cancer, EGFR-mutant NSCLC and HR+/HER2-negative breast cancer. (vcbeathealth.com)

The next question is whether Biokin can turn one breakthrough asset into a repeatable oncology platform.

BL-M14D1, T-Bren, SI-B001, the next-generation ADC portfolio, GNC multispecific antibodies and the emerging ARC platform will therefore become increasingly important measures of the company’s long-term value.

Financially, the strategy is expensive. Biokin recorded a RMB1.64 billion net loss in H1 2026, reflecting the scale of investment required to operate numerous late-stage and global trials. (marketscreener.com)

But the company has several advantages that many emerging biotechs lack: an established commercial pharmaceutical business, a Shanghai listing, substantial BMS economics, an increasingly valuable commercial oncology asset, in-house manufacturing, a U.S. R&D subsidiary and potential future access to Hong Kong capital markets.

Biokin’s stated ambition is to build a globally competitive multinational oncology company with full global commercialization capabilities by 2029. (ir.baili-pharm.com)

If iza-bren continues to deliver across additional tumor types—and if even one or two of the company’s follow-on ADC, GNC or ARC programs replicate that success—Sichuan Biokin could evolve from a Chinese pharmaceutical company best known for a landmark licensing transaction into one of China’s most globally significant oncology drug developers.

COMPANY NEWS

References

Tags: